試す 金 - 無料
Why corporate borrowers need to track credit default swap rates
Mint Mumbai
|September 15, 2025
These determine capital costs by offering a market view of risks that goes beyond agency ratings
Discussions on sovereign ratings usually focus on how rating agencies view the creditworthiness of a country, as broadly judged by its government's management of fiscal and other balances, among other factors. This is an issue of prestige even for governments—like India's—that do not need to borrow in the international market. Ratings, however, matter more to Indian companies that borrow from abroad, given that India's sovereign rating serves as a ceiling on their own rating. A company can get a rating up to two notches higher than the sovereign in case its global operations justify it.
One way to view the impact of sovereign ratings on companies is to look at the interest rates they are asked to pay on their borrowings. Here, sovereign credit default swaps (CDS) are the key, as all private borrowing is benchmarked against these swap rates. A CDS is essentially a form of insurance taken by an investor while investing in a security where the CDS seller provides cover in case of a default. The swap rate, which is denoted in basis points, is the premium to be paid for the cover. Sovereigns are not usually expected to default, but sovereign CDS rates serve as anchors to assess the probability of a default by any entity operating in that country. These rates are based on actual transactions and hence reveal the market's view.
このストーリーは、Mint Mumbai の September 15, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Mint Mumbai からのその他のストーリー
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

